Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A1KU
|
|||
| Former ID |
DNC010247
|
|||
| Drug Name |
PF-3274167
|
|||
| Synonyms |
PF-3274167; Cligosiban; 900510-03-4; UNII-D361S17AIF; D361S17AIF; CHEMBL594828; 5-(3-(3-(2-chloro-4-fluorophenoxy)azetidin-1-yl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridine; Cligosiban [INN]; 5-{3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl}-2-methoxypyridine; SCHEMBL4126605; EX-A297; MolPort-044-567-557; BCP08878; ZINC38239529; BDBM50305506; AKOS030526977; CS-5337; HY-15023; PF3274167; B5924; PF 3274167; J-690387; Pyridine, 5-(3-(3-(2-chloro-4-fluorophenoxy)-1-azetidinyl)-5
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Female sexual arousal dysfunction [ICD-11: HA01.1; ICD-9: 302.7] | Discontinued in Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19ClFN5O3
|
|||
| Canonical SMILES |
COCC1=NN=C(N1C2=CN=C(C=C2)OC)N3CC(C3)OC4=C(C=C(C=C4)F)Cl
|
|||
| InChI |
1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3
|
|||
| InChIKey |
HNIFCPBQMKPRCX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 900510-03-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxytocin receptor (OTR) | Target Info | Inhibitor | [2] |
| Vasopressin V1a receptor (V1AR) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| cAMP signaling pathway | ||||
| Oxytocin signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Oxytocin receptor mediated signaling pathway | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Myometrial Relaxation and Contraction Pathways | ||||
| Oxytocin signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025596) | |||
| REF 2 | Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.